Thrombolytic

Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group

...lso be used to a lesser extent in the treatment of upper limb DVT and peripheral artery occlusion. PMT combines the direct delivery of "clot-busting" thrombolytic drugs with mechanical clot disruption, and is posited to be safer, more effective, and more efficient than CDT alone due to the lower dose of thrombol...

Rush University Medical Center orthopaedic experts examine overhead

...ough rare, neurovascular disorders cause significant damage and recovery may be difficult. Successful non-operative treatment methods include rest and thrombolytic and anticoagulation injections used to diffuse blood clots. However, thirty percent of throwers will not respond to conservative measures and will req...

Journal Chest: April news briefs

...tor for deep vein thrombosis (DVT) or blood clots, a new study suggests that patients who undergo podiatric surgery may have a relatively low risk for thrombolytic events. In a 5-year retrospective analysis, researchers from Kaiser Permanente Center for Health Research reviewed the charts of 7,264 patients who un...

Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression

...g of patent applications for the technology. Moreover, this is the second molecule that IMTECH has under license with Nostrum, the first being a novel thrombolytic clot-buster protein known as SMRX11. While SMRX11 was the first patented recombinant DNA based biopharmaceutical molecule licensed to a foreign pharma...

Stroke therapy window might be extended past nine hours for some

...smatch between the lesions suggests that a patient might still benefit from thrombolytic therapy." In the study, most patients with blockage in a proximal artery...indings suggest a need for a clinical trial to measure the effectiveness of thrombolytic therapy more than nine hours after the onset of an ischemic stroke." ...

January 2009 Mayo Clinic Women's HealthSource Highlights Stroke Symptoms, Personal Health Records and Volunteering

...n or unusual symptoms that seem to get better or that aren't painful." In years past, treatment options for stroke were limited. That's changed. thrombolytic drugs, also known as clot busters, are used to treat ischemic stroke and reduce the risk of permanent brain damage that can cause paralysis or problem...

Clot Dissolver Doesn't Boost Survival in Cardiac Arrest Patients

...idn't work as hoped in a trial, but they haven't given up on the idea. "In specific situations, those patients with pulmonary embolism, use of this thrombolytic agent can stabilize the patient and help the patient survive," said Dr. Bernd W. Böttiger, professor and head of the department of anesthesiology...

Portable CT increases chance of stroke survival and recovery

...cipated to increase the number of patients to whom thrombolytic therapy can be administered," said the study's lea...sel in the brain. Such strokes can be treated with thrombolytic therapy using a drug called tPA that dissolves the... number of stroke patients able to be treated with thrombolytic therapy within the three-hour window. Accordin...

WVU study demonstrates efficacy of CT perfusion in diagnosis of acute ischemic stroke

...n is a practical way to help busy emergency departments save precious time in stroke diagnosis, target treatment and reduce the risks of inappropriate thrombolytic use," said Ansaar T. Rai, MD, Assistant Professor of Neuro Radiology & Neurointerventional Radiology. "CT perfusion was able to pinpoint strokes with...

Eisai Inc. Supports Acting Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism

...formulations should be used, where possible. FRAGMIN(R) should be used with care in patients receiving oral anticoagulants, platelet inhibitors, and thrombolytic agents because of increased risk of bleeding (see PRECAUTIONS, Laboratory Tests). Aspirin, unless contraindicated, is recommended in patients treated ...

Thrombolytic in Medical Technology

Portable CT Increases Chance of Stroke Survival and Recovery

...cipated to increase the number of patients to whom thrombolytic therapy can be administered," said the study's lea...sel in the brain. Such strokes can be treated with thrombolytic therapy using a drug called tPA that dissolves the... number of stroke patients able to be treated with thrombolytic therapy within the three-hour window. Acc...

Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series

...equirement of CDT procedures. There were no reported bleeding complications related to the Trellis device in acute follow up and the dosage of thrombolytic drugs such as t-PA was reduced by 30% with use of the Trellis device compared to CDT. "Profound changes in the treatment paradigm for DVT are ...

ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin

...several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; the...

Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women

...Published as a supplement in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), Antithrombotic and thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition was developed by an international panel of 90 experts and includes more than...

Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein

...essfully completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum's Symmetrix subsidia... animal model utilized has been previously validated on other, FDA approved thrombolytic products such as tPA. More recently, a similar study with SMRX11, which Nos...

Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack

...s 600,000 new attacks and 320,000 recurrent attacks. After an acute myocardial infarction, early and successful myocardial reperfusion with the use of thrombolytic therapy such as tissue plasminogen activator (tPA) or primary percutaneous coronary intervention (PCI) is the most effective strategy for reducing the...

CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors

...e patients up to 24 hours after symptom onset and another which adds NeuroFlo treatment to the current standard of care -- intravenous delivery of the thrombolytic drug, t-PA. CoAxia, Inc. is a venture-backed, privately held, development-stage company focused on providing perfusion augmentation therapies that i...

ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)

...several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInve...

Is PCI Safe, Effective After Clot-Busters for Heart Attack?

...orming PCI after treating patients with clot-busting drugs -- also known as thrombolytic or fibrinolytic agents -- offered no benefit and might even be harmful. Since then, however, thrombolytic medications have changed, stents are routinely used, and interventional car...

ImaRx Therapeutics Transitions Business Strategy

...nase, the Company's first commercially available FDA approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmo...acy formularies at approximately 700 acute care hospitals. Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmo...

Thrombolytic in Medical Products

HYDROLYSER Thrombectomy Catheter 7F Dual Lumen

Description:...DROLYSER provides an efficient, patient-friendly alternative to surgery and thrombolytic therapy. Compatible with your existing contrast power injector. Fragment... a 360 vortex that fragments and aspirates thrombus into the exhaust lumen. thrombolytic material is discharged through the exhaust lumen into a collection bag....
Company:Cordis Corporation

HYDROLYSER Thrombectomy Catheter 6F Triple Lumen

Description:...catheter provides an efficient, patient-friendly alternative to surgery and thrombolytic therapy. Compatible with your existing contrast power injector. Fragmen...a 360 vortex that fragments and aspirates thrombus into the exhaust lumen. thrombolytic material is discharged through the exhaust lumen into a collection bag....
Company:Cordis Corporation

Vascular ClearWay Irrigating PTFE Balloon Catheter

Features:... More efficient thrombus removal Precision delivery of thrombolytic Soft, non-compliant PTFE balloon Low pressure (2-3 ATM) atraumatic balloon expansion Central RO marker aids in placement ...
Company:Atrium Medical Corporation

Thrombolytic in Medical Dictionary

Thrombolytic therapy

... thrombolytic drugs are used in medicine to dissolve blood clo...ant part of the normal hemostatic response ... of thrombolytic therapy began in ... Overview: thrombolytic therapy is of proven and substantial benefit fo...

Thrombolytic in Biological News

Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf

... with thalassemia major and thalassemia intermediate found that the rate of thrombolytic events was 1.75 percent. Surgical technique has played a role in develop...nd prophylactic anticoagulants any time thalassemic patients are exposed to thrombolytic risk factors such as surgery, prolonged immobilization or pregnancy. Oral c...

New compound reduces stroke damage

... thrombus within the blood vessel. Because of the lack of available stroke treatments, neuroprotective agents have also generated as much interest as thrombolytic therapies. The immunosuppressive drug FK506 (also known as Tacrolimus or Prograf®) is often administered to patients receiving transplants to preve...

Thrombolytic in Biological Technology

ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent

Transfer Paves the Way for the Phase III Clinical Development and Commercialization of THR-100 in Developing Countries LEUVEN, Belgium, September 4 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced the su...

The Coalition to Prevent Deep-Vein Thrombosis (DVT) RV Tour Takes to the Road to Educate the Nation About the Importance of DVT Risk Assessment

...04; 10:356-365. (5) Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and thrombolytic Therapy. Chest. 2004; 126(suppl): 338S-400S. ...

ThromboGenics N.V.: Business Update

...several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent in stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Ant...

ThromboGenics Announces Half Year Results 2008

...several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; the...

ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer

...several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; the...

ThromboGenics Announces Private Investors Acquire 8% Stake in the Company

...several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; the...

Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT

...ve and safe method of treating patients with acute DVT. The Trellis device is the only DVT treatment system that isolates the thrombus and targets the thrombolytic treatment. About Bacchus Vascular Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascu...

ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody

...several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioI...

ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results

... evaluated in a Phase I/II clinical trial in combination with tPA in patients suffering from acute ischemic stroke. About Urokinase Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. The product has been commercial...

ThromboGenics N.V. - Business Update

... after the stroke event, and with potentially fewer side-effects than other thrombolytic agents. The MITI IV study is placebo controlled and is evaluating the safet...hich is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics i...